These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 35027074)
1. (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. Sihag J; Di Marzo V Lipids Health Dis; 2022 Jan; 21(1):9. PubMed ID: 35027074 [TBL] [Abstract][Full Text] [Related]
2. Role of the Endocannabinoidome in Human and Mouse Atherosclerosis. Piscitelli F; Silvestri C Curr Pharm Des; 2019; 25(29):3147-3164. PubMed ID: 31448709 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis. Abolghasemi A; Manca C; Iannotti FA; Shen M; Leblanc N; Lacroix S; Martin C; Flamand N; Di Marzo V; Silvestri C Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830242 [TBL] [Abstract][Full Text] [Related]
4. Neurobiological Processes Induced by Aerobic Exercise through the Endocannabinoidome. Forteza F; Giorgini G; Raymond F Cells; 2021 Apr; 10(4):. PubMed ID: 33920695 [TBL] [Abstract][Full Text] [Related]
5. The gut microbiome, endocannabinoids and metabolic disorders. Iannotti FA; Di Marzo V J Endocrinol; 2021 Feb; 248(2):R83-R97. PubMed ID: 33337346 [TBL] [Abstract][Full Text] [Related]
6. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders . Di Marzo V Dialogues Clin Neurosci; 2020 Sep; 22(3):259-269. PubMed ID: 33162769 [TBL] [Abstract][Full Text] [Related]
7. Alterations of brain endocannabinoidome signaling in germ-free mice. Manca C; Shen M; Boubertakh B; Martin C; Flamand N; Silvestri C; Di Marzo V Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158786. PubMed ID: 32795503 [TBL] [Abstract][Full Text] [Related]
8. Investigating the alterations of endocannabinoidome signaling in the human small intestine in the context of obesity and type 2 diabetes. Rakotoarivelo V; Allam-Ndoul B; Martin C; Biertho L; Di Marzo V; Flamand N; Veilleux A Heliyon; 2024 Mar; 10(6):e26968. PubMed ID: 38515705 [TBL] [Abstract][Full Text] [Related]
9. Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. Castonguay-Paradis S; Lacroix S; Rochefort G; Parent L; Perron J; Martin C; Lamarche B; Raymond F; Flamand N; Di Marzo V; Veilleux A Sci Rep; 2020 Sep; 10(1):15975. PubMed ID: 32994521 [TBL] [Abstract][Full Text] [Related]
10. The emerging role of the endocannabinoidome-gut microbiome axis in eating disorders. Mir HD; Giorgini G; Di Marzo V Psychoneuroendocrinology; 2023 Aug; 154():106295. PubMed ID: 37229916 [TBL] [Abstract][Full Text] [Related]
11. Dietary food patterns as determinants of the gut microbiome-endocannabinoidome axis in humans. Castonguay-Paradis S; Perron J; Flamand N; Lamarche B; Raymond F; Di Marzo V; Veilleux A Sci Rep; 2023 Sep; 13(1):15702. PubMed ID: 37735572 [TBL] [Abstract][Full Text] [Related]
12. Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice. Lacroix S; Pechereau F; Leblanc N; Boubertakh B; Houde A; Martin C; Flamand N; Silvestri C; Raymond F; Di Marzo V; Veilleux A mSystems; 2019 Dec; 4(6):. PubMed ID: 31848310 [TBL] [Abstract][Full Text] [Related]
13. Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome. Di Marzo V; Silvestri C Nutrients; 2019 Aug; 11(8):. PubMed ID: 31434293 [TBL] [Abstract][Full Text] [Related]
14. Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. Manca C; Boubertakh B; Leblanc N; Deschênes T; Lacroix S; Martin C; Houde A; Veilleux A; Flamand N; Muccioli GG; Raymond F; Cani PD; Di Marzo V; Silvestri C J Lipid Res; 2020 Jan; 61(1):70-85. PubMed ID: 31690638 [TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Cani PD; Plovier H; Van Hul M; Geurts L; Delzenne NM; Druart C; Everard A Nat Rev Endocrinol; 2016 Mar; 12(3):133-43. PubMed ID: 26678807 [TBL] [Abstract][Full Text] [Related]
16. Dietary PUFAs and Exercise Dynamic Actions on Endocannabinoids in Brain: Consequences for Neural Plasticity and Neuroinflammation. Park Y; Watkins BA Adv Nutr; 2022 Oct; 13(5):1989-2001. PubMed ID: 35675221 [TBL] [Abstract][Full Text] [Related]
17. Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. Russo R; Cristiano C; Avagliano C; De Caro C; La Rana G; Raso GM; Canani RB; Meli R; Calignano A Curr Med Chem; 2018; 25(32):3930-3952. PubMed ID: 28215162 [TBL] [Abstract][Full Text] [Related]
18. A Lipidomics- and Transcriptomics-Based Analysis of the Intestine of Genetically Obese ( Suriano F; Manca C; Flamand N; Van Hul M; Delzenne NM; Silvestri C; Cani PD; Di Marzo V Cells; 2023 Jan; 12(3):. PubMed ID: 36766753 [TBL] [Abstract][Full Text] [Related]
19. The human fecal endocannabinoidome mediator profile is mainly defined by the fecal microbiota and diet. Castonguay-Paradis S; Parent L; St-Arnaud G; Perron J; Dumais É; Flamand N; Raymond F; Di Marzo V; Veilleux A J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39171571 [TBL] [Abstract][Full Text] [Related]
20. Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota. Suriano F; Manca C; Flamand N; Depommier C; Van Hul M; Delzenne NM; Silvestri C; Cani PD; Di Marzo V Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jan; 1867(1):159056. PubMed ID: 34606993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]